Results 101 to 110 of about 2,479 (192)

Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 241-254, January 2026.
Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel   +13 more
wiley   +1 more source

Screening of Novel Pharmacogenetic Candidates for Mercaptopurine-Induced Toxicity in Patients With Acute Lymphoblastic Leukemia

open access: yesFrontiers in Pharmacology, 2020
A small proportion of patients with acute lymphoblastic leukemia (ALL) may experience severe leukopenia after treating with 6-mercaptopurine (6MP), which can be largely explained by germline variants in TPMT and NUDT15.
Minyuan Cao   +11 more
doaj   +1 more source

Personalization of thiopurine therapy: Current recommendations and future perspectives

open access: yesActa Pharmaceutica
Despite great therapeutic advances in the field of biologics, small synthetic molecules such as thiopurines, including azathioprine, mercaptopurine, and thioguanine, remain an important therapeutic pillar in the treatment of inflammatory bowel disease ...
Urbančič Dunja   +3 more
doaj   +1 more source

Impacto de la mutación homocigota en Nudix hidrolasa 15 sobre la mielosupresión con 6-mercaptopurina en una niña europea con leucemia linfoblástica aguda: A propósito de un caso [PDF]

open access: yes, 2023
A 6-year-old girl diagnosed with intermediate-risk acute lymphoblastic leukemia (ALL) presented with severe myelotoxicity and multiple infections during phase IB induction treatment with 6-mercaptopurine (6-MP).
García-Fumero, Ricardo   +5 more
core   +1 more source

Pharmacotherapy Risks in Rare Genetic Diseases: Cross‐Referencing ACMG Secondary Findings v3.2 List With Clinical Databases

open access: yesClinical and Translational Science, Volume 19, Issue 1, January 2026.
ABSTRACT Clinical genomics and pharmacogenomics have largely remained separate fields, though some genetic variants have overlapping disease risk and drug implications. However, the extent of this overlap is not well studied. To explore this gap, we cross‐referenced genes from the American College of Medical Genetics Secondary Findings v3.2 list with ...
Josiah D. Allen   +3 more
wiley   +1 more source

PHARMACOGENOMICS IN THE EMIRATI POPULATION: APPLICATIONS IN CARDIOVASCULAR DISEASES AND ONCOLOGY [PDF]

open access: yes, 2020
Pharmacogenetic variations contribute to interindividual differences in drug response. Advances in molecular techniques provided insights into interpopulation pharmacogenomic variations.
Al Mahairi, Zeina Nizar
core   +1 more source

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia [PDF]

open access: yes, 2019
The Asia-Pacific Working Group on inflammatory bowel disease (IBD) was established in Cebu, Philippines, under the auspices of the Asian Pacific Association of Gastroenterology with the goal of improving IBD care in Asia. This consensus is carried out in
Abdullah, M   +32 more
core   +1 more source

A comprehensive structural, biochemical and biological profiling of the human NUDIX hydrolase family [PDF]

open access: yes, 2017
The NUDIX enzymes are involved in cellular metabolism and homeostasis, as well as mRNA processing. Although highly conserved throughout all organisms, their biological roles and biochemical redundancies remain largely unclear.
A Battle   +67 more
core   +2 more sources

Pharmacogene Variation Consortium Gene Introduction: NUDT15 [PDF]

open access: yesClinical Pharmacology & Therapeutics, 2018
Jun J. Yang   +10 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy